939
Developers from the biopharmaceutical company Rubedo Life Sciences have announced the launch of a pilot phase of research on an experimental drug that affects aging cells, which are considered the main cause of the development of age-related diseases, because as they accumulate in the body, they provoke inflammation.
People's life expectancy is increasing all over the world, so scientists strive to provide the elderly with a higher quality of life. For this purpose, the drug RLS-1469 was developed, which targets the aging cells of the body and destroys them, writes New Atlas.
Currently, preclinical studies have shown the effectiveness of RLS-1469 in reducing aging skin cells, which are associated with the development of inflammatory diseases - atopic dermatitis and chronic psoriasis. In addition, skin biopsy samples from patients also showed a reduction in signs of aging.
The developers expect that the use of RLS-1469 will enable patients with chronic skin diseases to obtain a long-term therapeutic effect. "RLS-1469 should be the first disease-modifying therapy unlike the drugs available today," they said.
The results of pilot dermatology clinical trials will inform which diagnoses and conditions will be studied next.
